Managing Vomiting on Zepbound (tirzepatide): The HealthRX.com Step-by-Step Protocol

How common is vomiting on Zepbound?

The Zepbound label's pooled weight-reduction trials reported vomiting in 8% at 5 mg, 11% at 10 mg, and 13% at 15 mg vs 2% on placebo [1]. Any gastrointestinal adverse reaction occurred in 56% at each Zepbound dose vs 30% on placebo [1]. Severe gastrointestinal reactions occurred in 1.7%, 2.5%, and 3.1% vs 1% on placebo [1]. Gastrointestinal adverse reactions led to discontinuation in 1.9%, 3.3%, and 4.3% vs 0.5% [1]. The label says the majority of nausea, vomiting, and diarrhea events occurred during dose escalation and decreased over time [1]. It also says adverse reaction rates from different trials cannot be directly compared [1].

What dose changes does the label support?

The schedule starts at 2.5 mg once weekly for 4 weeks; 2.5 mg is for initiation and is not approved as a maintenance dose [1]. After 4 weeks, the dose goes to 5 mg, then can increase by 2.5 mg increments after at least 4 weeks on the current dose [1]. Maintenance for weight reduction is 5, 10, or 15 mg weekly; for OSA it is 10 or 15 mg weekly; the maximum is 15 mg weekly [1]. If patients do not tolerate a maintenance dose, the label says to consider a lower maintenance dose [1].

What does the label say to monitor during vomiting?

The label warns of acute kidney injury due to volume depletion; the majority of reported events occurred in patients with gastrointestinal reactions leading to dehydration, such as nausea, vomiting, or diarrhea [1]. It says to monitor renal function in patients reporting reactions that could lead to volume depletion, especially during dose initiation and escalation [1]. The label also warns of severe gastrointestinal reactions and says Zepbound is not recommended in patients with severe gastroparesis [1]. For pancreatitis, the label says to observe patients for signs and symptoms, which may include persistent or severe abdominal pain sometimes radiating to the back and which may or may not be accompanied by nausea or vomiting, and to discontinue Zepbound if pancreatitis is suspected and initiate appropriate management [1]. The label says the majority of patients who discontinued Zepbound because of adverse reactions did so during the first few months because of gastrointestinal adverse reactions [1].

What the label does not cover

The label names no antiemetic, dietary or hydration protocol for vomiting. Its concrete steps are dose increases at least 4 weeks apart, a lower maintenance dose if needed, renal-function monitoring when reactions could cause volume depletion, and watching for pancreatitis symptoms [1].